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Study Flow 
BES=biodegradable polymer biolimus-eluting stent, SES=durable polymer sirolimus-eluting stent, PCI=percutaneous coronary intervention. Note that we have no reliable data on 
the number of patients assessed for eligibility
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Baseline characteristics 
 Biodegradable polymer BES (N=857) Durable polymer SES (N=850) 
Age (years) 64·6 (10·8) 64·5 (10·7) 
Male 643 (75·0%) 634 (74·6%) 
Diabetes mellitus 223 (26·0%) 191 (22·5%) 
 Insulin requiring 81 (9·5%) 77 (9·1%) 
Hypertension 630 (73·5%) 618 (72·7%) 
Hypercholesterolemia 560 (65·3%) 580 (68·2%) 
Current smoker 206 (24·0%) 214 (25·2%) 
Family history of coronary artery disease 339 (39·6%) 374 (44·0%) 
History of  MI 276 (32·2%) 277 (32·6%) 
History of  PCI 312 (36·4) 312 (36·7%) 
Previous CABG 90 (10·5%) 107 (12·6%) 
Peripheral vascular disease 70 (8·2%) 63 (7·4%) 
Multi-vessel disease 209 (24·4%) 176 (20·7%) 
Left ventricular ejection fraction* (%) 55·9% (11·3) 55·4% (12·4) 
SYNTAX score† 13·2 (8·7) 13·3 (8·7) 
Acute coronary syndrome 470 (54·8%) 473 (55·7%) 
 ST-elevation MI 135 (15·8%) 140 (16·5%) 
 Non ST-elevation MI 145 (16·9%) 153 (18·0%) 
 Unstable angina 190 (22·2%) 180 (21·2%) 
Stable angina 387 (45·2%) 377 (44·4%) 
De-novo lesions only 788 (91·9%) 774 (91·1%) 
Off-label use 696 (81·2%) 665 (78·2%) 
Multivessel disease 209 (24·4%) 176 (20·7%) 
Small-vessel disease (RVD <2.75 mm) 585 (68·3%) 568 (66·8%) 
Long lesions (>20 mm) 262 (30·6%) 225 (26·5%) 
Number of lesions per patient 1·5 (0·7) 1·4 (0·7) 
Reference vessel diameter (mm) ‡ 2·60 (0·61) 2·60 (0·57) 
Minimum lumen diameter (mm) § 0·91 (0·50) 0·95 (0·52) 
Diameter stenosis (%) § 64·6% (17·9) 63·3% (18·2) 
 
Data are mean (SD) or number (%). MI=myocardial infarction, PCI=percutaneous coronary intervention, 
CABG=coronary artery bypass grafting, RVD=reference vessel disease,. *Left ventricular ejection fraction is 
available in  601 allocated to biolimus-eluting stent and 607 allocated to sirolimus-eluting stent. †678 patients in 
the biolimus-eluting stent group, and 673 in the sirolimus-eluting stent group.‡1246 assessed in the biolimus-
eluting stent group, and 1199 in the sirolimus-eluting stent group. §1209 assessed in the biolimus-eluting stent 
group, and 1186 in the SES group.  
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Definite stent thrombosis 
Kaplan-Meier curves for definite stent thrombosis through 4 years, overall and according to a landmark analysis 
at 1 year. BES=biodegradable polymer biolimus-eluting stent, SES=durable polymer sirolimus-eluting stent.  
4 
 
 
 
 
 
Stratified analysis of the primary endpoint at 4 years.  
One patient allocated to biolimus-eluting stent (one lesion) and two patients allocated to sirolimus eluting stent 
(two lesions) did not undergo any diagnostic or angiographic procedure after randomisation; lesion 
characteristics are unavailable and these patients could not be included in stratified analyses for left anterior 
descending artery, off -label use, de-novo lesions, small-vessel disease, and long lesions. MI=myocardial 
infarction. 
 
